Study of COVID-19 DNA Vaccine (AG0301-COVID19)

  • STATUS
    Recruiting
  • participants needed
    30
  • sponsor
    AnGes, Inc.
Send
Updated on 5 August 2020
See if I qualify
antibody test
covid-19
SARS
dna vaccine
acute respiratory syndrome (sars)

Summary

This study will assess the safety and immunogenicity of AG0301-COVID19 in healthy adult volunteers.

Description

This is a Phase 1/2, single-center, non-randomised, open-label, non-controlled trial. Approximately 30 healthy volunteers, male or female, aged 20-65, will be enrolled in the low dose group for the first 15 and the high dose group for the remaining 15.

Low dose group: 1.0 mg AG0301-COVID19 intramuscular (IM) (n = 15) High dose group: 2.0 mg AG0301-COVID19 IM (n = 15)

Details
Condition Covid 19
Age 20years - 65years
Treatment AG0301-COVID19
Clinical Study IdentifierNCT04463472
SponsorAnGes, Inc.
Last Modified on5 August 2020

Eligibility

 Yes No Not Sure

Inclusion Criteria

Subjects who have obtained written consent voluntarily to participate in this clinical trial
Subjects whose age at the time of obtaining consent is 20 years to 65 years
Subjects who are negative for SARS-CoV-2 by PCR test
Subjects who are negative for both SARS-CoV-2 IgM antibody and SARS-CoV-2 IgG antibody by antibody test

Exclusion Criteria

Subjects with symptoms of suspected COVID-19 infection (respiratory symptoms, headache, malaise, olfactory disorders, taste disorders, etc.)
Subjects with a history of COVID-19 (hearing from subjects)
Subjects who have participated in unapproved vaccine clinical trials
Subjects with axillary temperature of 37.0 degree or higher
Subjects who have a history of anaphylaxis
Subjects who have serious renal, liquid, respiratory, liver, kidney, digestive, and neuropsychiatric history has a current medical history
Subjects with a history of convulsion or epilepsy
Subjects with a history of diagnosis of immunodeficiency
Subjects who have a close relative (within 3rd degree) of congenital immunodeficiency
Subjects who have a history of bronchial asthma
Subjects who had a fever of 39.0C or higher within 2 days after the last vaccination, and those who suspected allergy such as a systemic rash
Females who wish to become pregnant from the date of study registration to 12 weeks after the first inoculation of the investigational drug, and pregnant females who are breast-feeding. In addition, females who may become pregnant and their male sexual partners should use appropriate contraceptives (pill), condoms, vasectomy, tubal ligation, diaphragm, intrauterine devices, spermicides, intrauterine hormone-releasing system, etc. from the study entry date until 12 weeks after vaccination
Subjects who have participated in clinical trials of other unapproved drugs and received the investigational drug within 4 weeks before the start of this clinical trial (starting from vaccination day)
Subjects who have been received a live vaccine, inactivated vaccine, or toxoid within 4 weeks before the start of this clinical trial (starting from vaccination day)
Subjects who have been administered with drugs that affect the immune system (excluding external preparations) such as immunomodulators (DMARDs, etc.), immunosuppressants, biologics, etc. within 4 weeks from vaccination
Subjects who received blood transfusion or gamma globulin therapy within 12 week before vaccination, or high-dose gamma globulin therapy (200 mg/kg or more) within 24 weeks before vaccination
Subjects who have a history of overseas travel within 4 weeks before the start of the clinical trial (starting from vaccination day)
Subjects who are unable to comply with the clinical trial protocol and follow up (for mental, family, social or geographical reasons)
Subjects who are judged to be ineligible for this clinical trial by the investigator
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

antibody test
covid-19
SARS
dna vaccine
acute respiratory syndrome (sars)

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.